Nido Biosciences

🗓 Founded 2018👥 18 employees💰 Last funded Apr 2023
Biotechnology Research
LinkedIn
Nido Bio is translating today’s neuroscience breakthroughs into tomorrow’s treatments for severe neurological diseases. Leveraging human genetics, we develop precision medicines that address the fundamental biology of disease and restore healthy cell function. NIDO-361, our clinical-stage candidate, is a treatment for Spinal and Bulbar Muscular Atrophy which is a rare and debilitating neuromuscular disease. Additional pipeline programs center around a novel target with the potential to address multiple disease mechanisms and that has broad clinical application across neurodegenerative and peripheral inflammatory diseases. We are creating a sustainable pipeline for the company by utilizing a functional genomics discovery platform based on human cell lines to identify novel targets. Through our approach we seek to transform patient lives in meaningful ways. www.nidobio.com.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2018
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Nido Biosciences?
Nido Biosciences has 1 investors on record on gritt.io, 1 mid-stage.
When did Nido Biosciences last raise funding?
The most recent investment in Nido Biosciences recorded on gritt.io was in April 2023.
When was Nido Biosciences founded?
Nido Biosciences was founded in 2018.
What industry is Nido Biosciences in?
Nido Biosciences operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.